Bioxytran (BIXT) Return on Sales (2010 - 2018)

Bioxytran (BIXT) posted Return on Sales of 0.0% for Q2 2018, up 99.39% sequentially from 0.02% in Q1 2018, and up 7.0% YoY from 0.0% in Q2 2017.

Bioxytran (BIXT) Return on Sales (2010 - 2018) Analysis & Trends

Bioxytran has reported Return on Sales for 9 years, with the latest figure at 0.0% in Q2 2018.

Quarterly Return on Sales rose 7.0% year-over-year to 0.0% in Q2 2018, while the trailing twelve-month figure through Jun 2018 was 0.0% (up 2.0% YoY) and the FY2017 annual result came in at 0.02%, up 1.0% from the prior year.
Return on Sales grew to 0.0% in Q2 2018 per BIXT's latest filing, from 0.02% in the prior quarter.
Over five years, Return on Sales peaked at 0.19% in Q4 2014 and troughed at 0.32% in Q2 2015.
A 5-year average of 0.04% and a median of 0.02% in 2014 frame the typical range for Return on Sales.
The sharpest annual moves came in 2015 and 2016: Return on Sales plunged 31 bps in 2015, then gained 30 bps in 2016.
Over 5 years, Return on Sales stood at 0.19% in 2014, then sank by 99 bps to 0.0% in 2015, then surged by 1278 bps to 0.02% in 2016, then sank by 215 bps to 0.03% in 2017, then surged by 99 bps to 0.0% in 2018.
According to Business Quant data, Return on Sales over the past three periods registered 0.0%, 0.02%, and 0.03% for Q2 2018, Q1 2018, and Q4 2017 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.00%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	0.00%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	0.00%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.00%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.00%
10	Bioxytran	2.52 Mn	2.27 Mn	-	-

Download Data